For the Inventor, By the Inventor

Enter assignee name

Lianyungang, China

Lianyungang Runzhong Pharmaceutical Co., Ltd.

USPTO Granted Patents = 26

CIPO Patents = 1

EPO Patents = 21

Forward Citations = 24

Loading Chart...

Loading Chart...

95 inventors (with patents filed for the assignee):

Yongxin Han (13 out of 21 patents)

Yong Peng (11 out of 26 patents)

Xiquan Zhang (10 out of 42 patents)

4. Yuandong Hu (10 out of 15 patents)

5. Hong Luo (10 out of 17 patents)

6. Hongjiang Xu (9 out of 27 patents)

7. Hui Zhang (6 out of 116 patents)

8. Aiming Zhang (6 out of 13 patents)

9. Xin Tian (6 out of 16 patents)

10. Xijie Liu (6 out of 9 patents)

11. Yinghui Sun (6 out of 9 patents)

12. Ling Yang (6 out of 27 patents)

13. Dengming Xiao (6 out of 14 patents)

14. Li Zhu (5 out of 36 patents)

15. Liguang Dai (5 out of 6 patents)

26 patents: Sort by Forward Citations

1. 12447154 - Use of pyrrolopyrimidine compound for treating hemophagocytic syndrome (2025-10-21),

2. 12097204 - Solid pharmaceutical composition containing 1,3,5-triazine derivative or salt thereof (2024-09-24),

3. 12030880 - Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof (2024-07-09),

4. 11773079 - Crystalline forms of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine (2023-10-03),

5. 11254665 - Crystalline sulfamide compound (2022-02-22),

6. 11203586 - Iridinesulfonamide compound and use method thereof (2021-12-21),

7. 11111240 - Sultam compound and application method thereof (2021-09-07),

8. 11098060 - Macrocycle containing aminopyrazole and pyrimidine and pharmaceutical composition and use thereof (2021-08-24),

9. 11021464 - Crystalline forms of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine methanesulfonic acid salt (2021-06-01),

10. 10858340 - Crystal of salt of quinazoline derivative (2020-12-08),

11. 10829492 - Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor (2020-11-10),

12. 10822319 - Crystal of DPP-IV long-acting inhibitor and salt (2020-11-03),

13. 10766901 - Preparation method for chiral pyrrolopyrimidine compound (2020-09-08),

14. 10745383 - 1,3,5-triazine derivative and method of using same (2020-08-18),

15. 10626118 - Pyrrolopyrimidine crystal for preparing JAK inhibitor (2020-04-21),

LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. is a renowned pharmaceutical company specializing in the research, development, manufacturing, and distribution of high-quality pharmaceutical products. With a strong commitment to innovation, Runzhong Pharma has been at the forefront of breakthrough medical advancements, continuously delivering effective and safe solutions for various diseases and ailments. Our state-of-the-art facilities and dedicated team of experts ensure the highest standards of quality control and adherence to international regulations. We strive to improve global healthcare by providing affordable, accessible, and reliable pharmaceuticals that enhance the well-being of individuals worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

26 Patents

#1 in Lianyungang

#1,042 in China

#24,073 in the World

Lianyungang, China

Lianyungang Runzhong Pharmaceutical Co., Ltd.

Forward Citations = 24

95 inventors:

Yongxin Han (13 out of 21 patents)

Yong Peng (11 out of 26 patents)

Xiquan Zhang (10 out of 42 patents)

4. Yuandong Hu (10 out of 15 patents)

5. Hong Luo (10 out of 17 patents)

Please report any incorrect information to support@idiyas.com

Loading…